Millennium Management’s AbCellera Biologics ABCL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-297,200
Closed -$3.16M – 7004
2022
Q2
$3.16M Buy
+297,200
New +$2.52M ﹤0.01% 3239

Other funds holding ABCL

Millennium Management's ABCL Position: Q3 2026 in Review

Millennium Management increased its AbCellera Biologics (ABCL) stake by 293% in Q3 2026, buying an estimated $14.4M and bringing the position to 2,038,187 shares worth $29.7M. The position accounts for 0.01% of the portfolio, ranked #1301.

Millennium Management first reported a position in ABCL in Q4 2020 and has held it in 24 quarters since. The position peaked at $31.5M in Q2 2022. 164 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.

  • Millennium Management held 2,038,187 shares of AbCellera Biologics worth $29.7M as of Q3 2026.
  • Millennium Management bought 1,519,616 AbCellera Biologics shares in Q3 2026, an estimated $14.4M.
  • AbCellera Biologics made up 0.01% of Millennium Management's portfolio in Q3 2026, its #1301 holding.
  • Millennium Management first reported a position in AbCellera Biologics in Q4 2020 and has held it in 24 quarters since.
  • Millennium Management's AbCellera Biologics position peaked at $31.5M in Q2 2022.
  • 164 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.

Based on Millennium Management's 13F filing for Q3 2026, filed 16 Nov 2026.